Michael Levy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6209442/publications.pdf

Version: 2024-02-01

180	11,291	50170	30848
papers	citations	46 h-index	102 g-index

184	184	184	7789
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.5	3,275
2	Eculizumab in Aquaporin-4â€“Positive Neuromyelitis Optica Spectrum Disorder. New England Journal of Medicine, 2019, 381, 614-625.	13.9	536
3	Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 3325-3345.	0.8	413
4	Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain, 2012, 135, 521-533.	3.7	306
5	Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica. JAMA Neurology, 2014, 71, 324.	4.5	258
6	Epidemiology of Neuromyelitis Optica in the United States. Archives of Neurology, 2012, 69, 1176-80.	4.9	239
7	Neuromyelitis optica. Nature Reviews Disease Primers, 2020, 6, 85.	18.1	232
8	Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, 2012, 1, 180-187.	0.9	217
9	Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Multiple Sclerosis Journal, 2015, 21, 678-688.	1.4	209
10	Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Multiple Sclerosis Journal, 2016, 22, 185-192.	1.4	185
11	Mitochondrial Regulation of Synaptic Plasticity in the Hippocampus. Journal of Biological Chemistry, 2003, 278, 17727-17734.	1.6	163
12	MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2018, 25, 66-72.	0.9	158
13	The Role of Mitochondrial Porins and the Permeability Transition Pore in Learning and Synaptic Plasticity. Journal of Biological Chemistry, 2002, 277, 18891-18897.	1.6	154
14	Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Multiple Sclerosis Journal, 2014, 20, 843-847.	1.4	154
15	The COVID-19 pandemic and the use of MS disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2020, 39, 102073.	0.9	153
16	Superficial siderosis: a case report and review of the literature. Nature Clinical Practice Neurology, 2007, 3, 54-58.	2.7	152
17	Racial differences in neuromyelitis optica spectrum disorder. Neurology, 2018, 91, e2089-e2099.	1.5	140
18	Neuromyelitis optica pathogenesis and aquaporin 4. Journal of Neuroinflammation, 2008, 5, 22.	3.1	138

#	Article	IF	Citations
19	In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology, 2013, 80, 1406-1414.	1.5	138
20	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.5	129
21	Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic. Current Treatment Options in Neurology, 2016, 18, 2.	0.7	116
22	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
23	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	0.9	110
24	Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. Multiple Sclerosis Journal, 2016, 22, 302-311.	1.4	106
25	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e134.	3.1	104
26	New therapies for neuromyelitis optica spectrum disorder. Lancet Neurology, The, 2021, 20, 60-67.	4.9	86
27	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e286.	3.1	85
28	Mortality in neuromyelitis optica is strongly associated with African ancestry. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e468.	3.1	83
29	MRI differences between MOG antibody disease and AQP4 NMOSD. Multiple Sclerosis Journal, 2020, 26, 1854-1865.	1.4	81
30	Neuromyelitis optica spectrum disorders in children and adolescents. Neurology, 2016, 87, S59-66.	1.5	78
31	Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Multiple Sclerosis Journal, 2020, 26, 1360-1371.	1.4	75
32	Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology, 2018, 90, e12-e21.	1.5	72
33	Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. Journal of the Neurological Sciences, 2015, 355, 59-63.	0.3	68
34	MOG antibodyâ€“associated encephalomyelitis/encephalitis. Multiple Sclerosis Journal, 2019, 25, 1427-1433.	1.4	67
35	Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. Neurology Research International, 2012, 2012, 1-13.	0.5	64
36	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	64

#	Article	IF	Citations
37	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	3.7	62
38	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
39	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	4.5	59
40	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14781-14786.	3.3	59
41	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology, 2017, 89, 2238-2244.	1.5	59
42	Immunopathogenesis of Neuromyelitis Optica. Advances in Immunology, 2014, 121, 213-242.	1.1	55
43	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	2.8	55
44	Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis. Stroke, 2012, 43, 120-124.	1.0	54
45	Use of MR Cell Tracking to Evaluate Targeting of Glial Precursor Cells to Inflammatory Tissue by Exploiting the Very Late Antigen-4 Docking Receptor. Radiology, 2012, 265, 175-185.	3.6	52
46	A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. Journal of Neurology, 2012, 259, 801-816.	1.8	49
47	Safe and Effective Intravenous Thrombolysis for Acute Ischemic Stroke Caused by Left Atrial Myxoma. Journal of Stroke and Cerebrovascular Diseases, 2009, 18, 398-402.	0.7	48
48	Needle type and the risk of post-lumbar puncture headache in the outpatient neurology clinic. Journal of the Neurological Sciences, 2011, 306, 24-28.	0.3	48
49	Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e5.	3.1	46
50	Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica. Acta Neuropathologica Communications, 2015, 3, 28.	2.4	44
51	Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Multiple Sclerosis and Related Disorders, 2019, 28, 64-68.	0.9	44
52	Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. Multiple Sclerosis and Related Disorders, 2017, 17, 116-122.	0.9	43
53	A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (United States), 2019, 98, e15944.	0.4	42
54	Twoâ€year observational study of deferiprone in superficial siderosis. CNS Neuroscience and Therapeutics, 2018, 24, 187-192.	1.9	41

#	Article	IF	Citations
55	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2018, 24, 1737-1742.	1.4	41
56	Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opinion on Investigational Drugs, 2018, 27, 265-271.	1.9	40
57	Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. Journal of the Neurological Sciences, 2018, 384, 96-103.	0.3	40
58	Bevacizumab is safe in acute relapses of neuromyelitis optica. Clinical and Experimental Neuroimmunology, 2015, 6, 413-418.	0.5	39
59	Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology, 2015, 84, 1805-1815.	1.5	39
60	Rethinking high-risk groups in COVID-19. Multiple Sclerosis and Related Disorders, 2020, 42, 102139.	0.9	39
61	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	4.5	39
62	Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2018, 23, 78-82.	0.9	38
63	Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e269.	3.1	37
64	Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. Multiple Sclerosis and Related Disorders, 2021, 55, 103189.	0.9	37
65	Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Multiple Sclerosis and Related Disorders, 2017, 17, 198-201.	0.9	36
66	Predictors of recurrence following an initial episode of transverse myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e4.	3.1	35
67	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 39, 101920.	0.9	35
68	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e583.	3.1	33
69	Radiological characteristics of myelin oligodendrocyte glycoprotein antibody disease. Multiple Sclerosis and Related Disorders, 2019, 29, 15-22.	0.9	33
70	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	3.1	32
71	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	1.4	32
72	Regenerative cellular therapies for neurologic diseases. Brain Research, 2016, 1638, 88-96.	1.1	31

#	Article	IF	Citations
73	n-Dodecyl-Î²-d-Maltoside Inhibits Aggregation of Human Interferon-Î²-1b and Reduces Its Immunogenicity. Journal of NeuroImmune Pharmacology, 2011, 6, 158-162.	2.1	30
74	Deferiprone Reduces Hemosiderin Deposits in the Brain of a Patient with Superficial Siderosis: Fig 1.. American Journal of Neuroradiology, 2011, 32, E1-E2.	1.2	30
75	Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D. International Journal of MS Care, 2019, 21, 129-134.	0.4	29
76	The Other Half of Hebb. Molecular Neurobiology, 2002, 25, 051-066.	1.9	28
77	Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. Journal of Neuroimmunology, 2010, 221, 68-72.	1.1	27
78	Prevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective study. Clinical and Experimental Neuroimmunology, 2018, 9, 155-161.	0.5	26
79	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Multiple Sclerosis and Related Disorders, 2021, 47, 102641.	0.9	26
80	What do we know about brain contrast enhancement patterns in neuromyelitis optica?. Clinical Imaging, 2016, 40, 573-580.	0.8	25
81	Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results. Journal of Neurology, 2017, 264, 2284-2292.	1.8	25
82	Update on neuromyelitis optica spectrum disorder. Current Opinion in Ophthalmology, 2020, 31, 462-468.	1.3	24
83	Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. Current Neuropharmacology, 2020, 19, 220-232.	1.4	24
84	Lactase deficiency in Mexican-American males. American Journal of Clinical Nutrition, 1972, 25, 869-870.	2.2	23
85	Passively transferred human NMO-IgG exacerbates demyelination in mouse experimental autoimmune encephalomyelitis. BMC Neurology, 2013, 13, 104.	0.8	23
86	Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Multiple Sclerosis and Related Disorders, 2019, 28, 60-63.	0.9	23
87	Scrambler therapy improves pain in neuromyelitis optica. Neurology, 2020, 94, e1900-e1907.	1.5	22
88	Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice. Neurology and Therapy, 2021, 10, 767-783.	1.4	22
89	Low Serum Vitamin D Levels and Recurrent Inflammatory Spinal Cord Disease. Archives of Neurology, 2012, 69, 352.	4.9	21
90	Spinal Movement Disorders in Neuromyelitis Optica: An Underâ€recognized Phenomenon. Movement Disorders Clinical Practice, 2016, 3, 596-602.	0.8	21

#	Article	IF	Citations
91	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurology and Therapy, 2022, 11, 123-135.	1.4	21
92	Diagnosing CNS Vasculitis. Neurologist, 2012, 18, 233-238.	0.4	19
93	Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD. Multiple Sclerosis Journal, 2021, 27, 1738-1748.	1.4	19
94	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Multiple Sclerosis and Related Disorders, 2022, 57, 103352.	0.9	19
95	Review of animal models of neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2012, 1, 174-179.	0.9	16
96	Dry beriberi mimicking Guillainâ€“Barre syndrome as the first presenting sign of thiamine deficiency. European Journal of Neurology, 2012, 19, e14-5.	1.7	16
97	Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. Journal of Neuroimmunology, 2018, 324, 22-25.	1.1	16
98	Noninvasive Monitoring of Immunosuppressive Drug Efficacy to Prevent Rejection of Intracerebral Glial Precursor Allografts. Cell Transplantation, 2012, 21, 2149-2157.	1.2	15
99	Reversible Chest Tube Horner Syndrome. Journal of Neuro-Ophthalmology, 2008, 28, 212-213.	0.4	13
100	Cognition, mood, and purpose in life in neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences, 2016, 362, 85-90.	0.3	13
101	Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 30, 231-235.	0.9	13
102	Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. Journal of Neuroimmunology, 2021, 360, 577702.	1.1	13
103	Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort. Frontiers in Neurology, 0, 13, .	1.1	13
104	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. Multiple Sclerosis and Related Disorders, 2021, 53, 103155.	0.9	12
105	Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review. Journal of Neuro-Ophthalmology, 2022, 42, 154-162.	0.4	12
106	The Preoperative Neurological Evaluation. Neurohospitalist, The, 2013, 3, 209-220.	0.3	11
107	Sepsis risk factors in infants with congenital diaphragmatic hernia. Annals of Intensive Care, 2017, 7, 32.	2.2	11
108	Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. Pain Management Nursing, 2019, 20, 580-591.	0.4	11

#	Article	IF	Citations
109	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. Multiple Sclerosis and Related Disorders, 2020, 41, 102027.	0.9	11
110	Rituximab during pregnancy in neuromyelitis optica: A case report. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e542.	3.1	11
111	Is EBV the cause of multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2022, 58, 103636.	0.9	11
112	Implications of Low-Titer MOG Antibodies. Multiple Sclerosis and Related Disorders, 2022, 59, 103746.	0.9	10
113	Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e510.	3.1	9
114	Risk of Hematoma From Aspirin or Clopidogrel Owing to Lumbar Puncture. Mayo Clinic Proceedings, 2019, 94, 1552-1555.	1.4	9
115	Rodent Models of Optic Neuritis. Frontiers in Neurology, 2020, 11, 580951.	1.1	9
116	Bright spotty lesions as an imaging marker for neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2022, 28, 1663-1666.	1.4	9
117	Auditory Profile in Superficial Siderosis of the Central Nervous System. Otology and Neurotology, 2013, 34, 611-619.	0.7	8
118	Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders. American Journal of Neuroradiology, 2017, 38, 949-953.	1.2	8
119	Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2019, 33, A1-A2.	0.9	8
120	MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology. American Journal of Neuroradiology, 2019, 40, 1427-1432.	1.2	8
121	Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. American Journal of Neuroradiology, 2019, 40, 726-731.	1.2	8
122	Cognitive functions in Egyptian neuromyelitis optica spectrum disorder.. Clinical Neurology and Neurosurgery, 2020, 189, 105621.	0.6	8
123	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	1.8	8
124	Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. Journal of Neuroimmunology, 2015, 287, 29-30.	1.1	7
125	Vaccines and disease-modifying treatments. Multiple Sclerosis and Related Disorders, 2018, 26, A1-A2.	0.9	7
126	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 2021, 50, 102849.	0.9	7

#	Article	IF	Citations
127	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. Multiple Sclerosis and Related Disorders, 2021, 53, 103080.	0.9	7
128	Evidence for classic complement activity in neuromyelitis optica. , 2014, 33, 251-252.		7
129	Case Report: Scrambler Therapy for Treatment-Resistant Central Neuropathic Pain in a Patient with Transverse Myelitis. International Journal of MS Care, 2019, 21, 76-80.	0.4	7
130	Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies. Multiple Sclerosis and Related Disorders, 2022, 57, 103332.	0.9	7
131	Expanding the spectrum of MOG antibody disease. Multiple Sclerosis Journal, 2020, 26, 515-516.	1.4	6
132	Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. Journal of the Neurological Sciences, 2021, 428, 117546.	0.3	6
133	The ethics of placebo controlled clinical trials in NMO â€“ A balance of risks. Multiple Sclerosis and Related Disorders, 2015, 4, 512-514.	0.9	5
134	B cell therapy and the use of RNA-based COVID-19 vaccines. Multiple Sclerosis and Related Disorders, 2021, 49, 102887.	0.9	5
135	Optic Neuritisâ€“Independent Retinal Atrophy in Neuromyelitis Optica Spectrum Disorder. Journal of Neuro-Ophthalmology, 2022, 42, e40-e47.	0.4	5
136	B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20. ImmunoTargets and Therapy, 2021, Volume 10, 325-331.	2.7	5
137	Finding NMO. Neurology, 2008, 70, 334-335.	1.5	4
138	Does Aquaporin-4â€“Seronegative Neuromyelitis Optica Exist?. JAMA Neurology, 2014, 71, 271.	4.5	4
139	Familial monophasic acute transverse myelitis due to the pathogenic variant in VPS37A. Neurology: Genetics, 2018, 4, e213.	0.9	4
140	Aquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected Progression. Cancer Investigation, 2019, 37, 67-72.	0.6	4
141	Ten years of iron chelation in a patient with superficial siderosis. Neurological Sciences, 2019, 40, 1947-1949.	0.9	4
142	Paroxysmal symptoms in neuromyelitis optica spectrum disorder: Results from an online patient survey. Multiple Sclerosis and Related Disorders, 2020, 46, 102578.	0.9	4
143	Multiple Sclerosis and Vitamin D â€“ Caviar or a Dogâ€™s Dinner?. Multiple Sclerosis and Related Disorders, 2019, 28, A1-A2.	0.9	3
144	Interleukin-6 receptor blockade for the treatment of NMOSD. Lancet Neurology, The, 2020, 19, 370-371.	4.9	3

#	Article	IF	Citations
145	Air pollution and multiple sclerosis risk. Multiple Sclerosis and Related Disorders, 2021, 48, 102797.	0.9	3
146	A point-of-care diagnostic test for aquaporin-4 antibody seropositive neuromyelitis optica. Multiple Sclerosis and Related Disorders, 2022, 60, 103716.	0.9	3
147	Treatment outcomes of first-ever episode of severe optic neuritis. Multiple Sclerosis and Related Disorders, 2022, 66, 104020.	0.9	3
148	What Is the True Clinicopathologic Spectrum of Neuromyelitis Optica?â€"Reply. JAMA Neurology, 2013, 70, 272.	4.5	2
149	Neuromyelitis optica unmasked by a spinal dural arteriovenous fistula. Journal of Neuroimmunology, 2016, 300, 18-20.	1.1	2
150	A Novel GFAP Mutation in Late-Onset Alexander Disease Showing Diffusion Restriction. Journal of		

#	Article	IF	Citations
163	Should our treatment target in MS include the intrathecal plasma cell response?. Multiple Sclerosis and Related Disorders, 2019, 27, A1-A2.	0.9	1
164	Ageing and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 38, 101953.	0.9	1
165	Minimally-invasive Technique for Injection into Rat Optic Nerve. Journal of Visualized Experiments, 2015, , e52249.	0.2	0
166	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2018, 20, A1-A2.	0.9	0
167	Recurrent Dysarthria and Ataxia in a Young Girl. JAMA Neurology, 2018, 75, 125.	4.5	0
168	2189 Scrambler therapy: Potential new treatment for central neuropathic pain?. Journal of Clinical and Translational Science, 2018, 2, 47-47.	0.3	0
169	Is Corticospinal Tract Degeneration Caused by SjÃ¶gren Syndrome?. Journal of Clinical Neurology		